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Because many diseases of the Western Hemisphere are hormone-dependent cancers, we have postulated that the Western diet, compared to a
vegetarian or semivegetarian diet, may alter hormone production, metabolism, or action at the cellular level by some biochemical mechanisms.
Recently, our interest has been mainly focused on the cancer-protective role of some hormonelike diphenolic phytoestrogens of dietary origin, the
lignans and the isoflavonoids. The precursors of the biologically active compounds originate in soybean products (mainly isoflavonoids), whole grain
cereal food, seeds, and probably berries and nuts (mainly lignans). The plant lignan and isoflavonoid glycosides are converted by intestinal bacteria to
hormonelike compounds with weak estrogenic but also antioxidative activity; they have now been shown to influence not only sex hormone
metabolism and biological activity but also intracellular enzymes, protein synthesis, growth factor action, malignant cell proliferation, differentiation,
and angiogenesis in a way that makes them strong candidates for a role as natural cancer-protective compounds. Epidemiologic investigations
strongly support this hypothesis because the highest levels of these compounds in the diet are found in countries or regions with low cancer
incidence. This report is a review on recent results suggesting that the diphenolic isoflavonoids and lignans are natural cancer-protective
compounds. - Environ Health Perspect 103(Suppl 7):103-1 12 (1995)
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Introduction
Numerous epidemiologic and migrant
studies support the view that the Western
diet is one of the main factors causing the
high incidence of the so-called Western
diseases (1-4), among which we include
the major hormone-dependent cancers,
colon cancer, and coronary heart disease.
Because all these diseases to various extents
are related to sex hormones or sex hormone
metabolism (5-7), we have postulated that
the Western diet, compared to the vegetar-
ian or semivegetarian diet in some develop-
ing and Asian countries, may alter
hormone production, metabolism, or
action at the cellular level by some bio-
chemical mechanisms. Recently, our inter-
est has been focused on the biological role
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of two groups of hormonelike diphenolic
phytoestrogens of dietary origin, the lig-
nans and the isoflavonoids; they have simi-
lar molecular weights and metabolism as
the steroids, but partly with dearly differ-
ent biological effects in the cells. These
compounds, which mainly occur in soy-
bean and whole-grain products, various
seeds, and other similar food components,
have now been shown to influence not
only sex hormone metabolism and biologi-
cal activity but also intracellular enzymes,
protein synthesis, growth factor action,
malignant cell proliferation, and angiogen-
esis in away that makes them strong candi-
dates for a role as cancer-protective
compounds. This review discusses those
compounds that are measurable in the
mammalian organism.
Lignans and Isoflavonoids
in Foods
Since 1931 it has been well known that soy-
beans contain high amounts (up to
100-300 mg/100 g) ofthe glycosides ofthe
two isoflavones daidzein and genistein (8,9).
Much later, a third major compound,
glycitein, was found also as a glycoside (10).
Small amounts of these three compounds
occur in the free form. Fermented soy may
contain a catechol conversion product of
glycitein, 6,7,4'-trihydroxyisoflavone
(11,12). Furthermore, small amounts
(about 5 gI00 g) ofthe isoflavone coume-
strol have been found (13). Soy sauce does
not contain any isoflavones except the lig-
nan precursor coniferyl alcohol (14).
Recently, the content ofdaidzein and genis-
tein glycosides in various soy bean products
weredetermined (15).
We have developed new methodologies
for the assay of phytoestrogens in meal,
flour, and soy products using gas chro-
matography-mass spectrometry (GC-MS);
the lignan secoisolariciresinol has been mea-
sured in soy meal, and the concentrations
are relativelylow.
The mammalian lignans seem to be
mainly derived from grains and seeds and
probably also berries and nuts. Our studies
on fractionated meals of wheat and rye
seem to indicate that the precursors
matairesinol and secoisolariciresinol, both
present in meal ofthese grains, are present
in the aleurone layer ofthe grain. This cel-
lular layer is tightly bound to the fiber
layer, and the liberation of the precursors
from theseveryresistant cells is difficult.
Phytoestrogens Identified
in Man
When consumed, the plant isoflavonoids
and lignans undergo many metabolic con-
versions in the gut, which results in the for-
mation of hormonelike compounds with
estrogen activity and the ability to bind
weakly to estrogen receptors (16). About
15 years ago, two cyclically occurring
unknown compounds, now called entero-
lactone and enterodiol, were detected in the
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urine of the female vervet monkey and in
women; these compounds were subse-
quently identified independently by two
groups (17,18). Furthermore, small
amounts offourplant lignans (matairesinol,
lariciresinol, isolariciresinol, and secoisolari-
ciresinol) have been identified in human
urine (19,20); 7'-hydroxymatairesinol and
7'-hydroxyenterolactone were also tenta-
tively identified in urine (21).
The isoflavonoid phytoestrogens are
heterocyclic phenols with a close similarity
in structure to estrogens and a diphenolic
character similar to that of lignans. They
occur in numerous plants, and many stud-
ies have shown that they have hormonal
effects in animals (22), the most important
being the clover disease. The following
isoflavonoid phytoestrogens have been
identified or detected in human urine in
this laboratory: formononetin, methyl-
equol, daidzein, dihydrodaidzein, 0-
demethylangolensin, genistein, and
3',7-dihydroxyisoflavan. Equol was identi-
fied independently in two laboratories
(5,23). Recently, glycitein was also
identified in human urine, and five iso-
flavonoid metabolites (6'-hydroxy-0-
demethylangolensin, dihydrogenistein,
dehydro-O-demethylangolensin, and two
isomers of tetrahydrodaidzein) were tenta-
tively identified (Figure 1)(24).
Metabolism of
Phytoestrogens in Man
The literature on the origin, formation,
and metabolism of the phytoestrogens in
animals (22) and in man (16,21,25) has
been reviewed and therefore only a few
points will be discussed here.
Equol and O-demethylangolensin are
most likely formed, as in sheep, by intesti-
nal bacterial action from formononetin and
daidzein present in foodstuffs such as soy
products. Some people are unable to pro-
duce equol or they excrete this isoflavane in
very low amounts [H. Adlercreutz, unpub-
lished results; (16,26)]. Of the isoflavo-
noids, we can now determine daidzein,
0-demethylangolensin, equol, and genis-
tein in plasma (27), urine (28), and feces
(29) allowing studies on absorption and
metabolism ofthese compounds.
The mammalian lignans enterolactone
and enterodiol are formed from plant pre-
cursors by the action ofintestinal bacteria.
The lignan matairesinol is converted to
enterolactone and secoisolariciresinol is con-
verted to enterodiol; enterodiol may be oxi-
dized to enterolactone (16). We have now
established by gas chromatography-mass
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Figure 1. Structure ofthe most important isoflavonoids and lignans identified by human biological samples.
spectroscopy (GC-MS) techniques that the
plant lignans are localized close to the
outer fiber-containing layers of the grain
called the aleurone layer, which contains
phytin, polyphenols, enzyme inhibitors,
and other compounds generally regarded
as antinutritional factors. Modern milling
techniques usually eliminate this fraction
because it is tightly bound to the fiber
layer, which does not occur in the prod-
ucts supplied to the market for consump-
tion, with some exceptions. This occurs
particularly in Western societies. It should
be mentioned that administration of
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antibiotics almost completely eliminates
the formation ofenterolactone and entero-
diol from plant precursors in the gut
(30,31). Following further development of
our methodology (28), we can now ana-
lyze matairesinol, secoisolariciresinol,
enterodiol, and enterolactone in urine,
plasma, and feces. Many of these com-
pounds have also been identified and mea-
sured in cow's milk (32). Enterolactone
concentration is high in human and
bovine semen (33) and some lignans and
isoflavonoids have been identified and
measured by GC-MS in saliva, breast aspi-
rate or cyst fluid, and prostatic fluid by
GC-MS (34).
Phytoestrogen Levels
in Various Populations
A summary ofour results regarding urinary
lignan and isoflavonoid excretion in vari-
ous dietary groups of women and men,
including two groups of breast cancer
patients, has recently been presented (35).
None ofthe subjects had been treated with
antibiotics during the last 3 months.
With regard to lignans, the macrobiotic
women living in Boston, Massachusetts,
had the highest values, followed by the lac-
tovegetarian women living in Boston and
in Helsinki, Finland. The lowest lignan
values were found among the breast cancer
patients in Boston and in omnivorous
women in both Boston and Helsinki. In
our study of women in Hawaii that had
recently immigrated from the Orient, even
lower lignan values were found. These
immigrants had similar isoflavonoid values
as those consuming an omnivorous
Western diet, showing that they had very
rapidly left the soy products out of their
diet. Leaving the soy from the diet and not
consuming any whole-grain bread results
in very low lignan and isoflavonoid values
in urine, but the low-fat diet may still give
some protection against breast cancer. Low
lignan values were also found in the
Japanese men and women, who had very
high isoflavonoid values. Recent measure-
ments of urinary and plasma phytoestro-
gens in Japanese and Finnish men revealed
that despite low urinary lignan values in
the Japanese men the values for the
free+sulfate-conjugated lignans in plasma
were as high as those in the Finnish men,
but the glucuronide values for enterolac-
tone were significantly lower (p< 0.001)
(H Markkanen, unpublished results). In an
earlier study we found that lignan excre-
tion in Japanese subjects was related to the
intake of whole soybeans (26), which
agrees well with our recent detection of
secoisolariciresinol in soybean meal.
Biological Effects of Lignans
and Isoflavonoids
In this connection only phytoestrogens
that have been measured in the human
organism will be considered. The lignans
enterolactone and enterodiol bind weakly
to rat uterine cytosol (JH Clark and H
Adlercreutz, unpublished data) but have no
detectable estrogenic activity in vivo in
mice (30). However, in four sensitive
assays ofestrogen activity in tissue culture,
including breast cancer cell lines, the lig-
nans were stimulatory and the effect could
be blocked by tamoxifen. No antiestro-
genic properties could be observed (36). In
another study enterolactone in vivo inhib-
ited estrogen-stimulated RNA synthesis in
rat uterine tissue when administered 22 hr
before estradiol (37). The concentrations
of enterolactone were very low, and it is
doubtful whether this result can be
repeated. We observed stimulatory effect of
enterolactone on MCF-7 breast cancer cell
growth in the absence of estradiol, but, at
slightly stimulatory or nonstimulatory
estradiol and physiological enterolactone
concentrations, we observed no stimulation
or a tendency to inhibition (38). Recently
enterolactone, but not enterodiol, was
shown to stimulate pS2 expression in MCF-
7 cells (39). These diverging results are
difficult to explain, but it has been suggested
(7,40) that the effect of exogenous weak
estrogens may be either agonistic or antago-
nistic depending on the level ofendogenous
estrogens; this has been experimentally
confirmedwith regard to coumestrol (40).
Many studies have shown that the
isoflavonoid phytoestrogens bind to estro-
gen receptors and have weak estrogenic
activity (36,41,42); they also have
significant estrogenic effects in animals and
in man (40,43-46). The most well-known
estrogenic effect of phytoestrogens is the
clover disease in Australian sheep (22).
Furthermore, definite antiestrogenic effects
have been observed in vivo because high
levels of synthetic estrogens seem to be
counteracted by administered isoflavonoids
or their presence in the diet (43,47,48).
Several isoflavonoids and lignans com-
pete with estradiol for the rat uterine
nuclear type II estrogen binding sites (49).
The highest affinity with regard to type II
site binding of the diphenolic compounds
that we found and measured in human
urine is shown by the isoflavones daidzein
and equol. Also, some lignans like
matairesinol, isolariciresinol, and enterolac-
tone show competition. These binding
sites seem to constitute a component ofthe
genome that regulates estrogen-stimulated
growth (50,51). Thus the antiestrogenic
effect ofthese compounds may be mediated
via this binding site.
Many plant lignans have been shown to
have anticarcinogenic, antiviral, bactericidic,
and fungistatic activities (16,52,53).
Enterolactone, the most abundant mam-
malian lignan, is a moderate inhibitor of
placental aromatase and competes with the
natural substrate androstenedione for the
enzyme (54). Other experiments with a
choriocarcinoma cell line UEG-3) showed
that enterolactone is very readily trans-
ferred from cell culture media into the
cells (54). Flavonoids, occurring in very
high amounts in the diet, are inhibitors of
the aromatase enzyme (55). Studies in
human preadipocytes show inhibition of
the aromatase enzyme to various degrees
by lignans, flavonoids, and isoflavonoids
(56,57). Most of the lignans and flavo-
noids are onlyweak inhibitors. However, a
diet rich in vegetables may, due to the
abundance of these compounds in the
diet, lead to sufficient concentrations (e.g.,
in fat cells) to reduce conversion ofandro-
stenedione to estrone, lowering risk for
estrogen-dependent cancer (58).
Genistein, an isoflavone that we
identified in human urine (28) and that
occurs in large amounts both in urine and
plasma ofJapanese subjects consuming a
traditional Japanese diet (26,59), is a
specific inhibitor oftyrosine-specific protein
kinases (except the p4O protein-tyrosine
kinase), topoisomerase II (7), and protein
histidine kinase (60). Protein-tyrosine
kinase activity is associated with cellular
receptors for epidermal growth factor, insu-
lin, insulinlike growth factor I, platelet-
derived growth factor, and mononuclear
phagocyte growth factor. The tyrosine
kinases seem to play an important role in
cell proliferation and transformation. The
enzyme has been associated with oncogene
products ofthe retroviral srcgene family and
is correlated with the ability ofretrovirus to
transform cells (61-64). Tyrosine kinase
activity is also associated with breast cancer
oncogene expression (65,66).
Stimulation ofthe Synthesis
ofSex Hormone-Binding
Globulin
Lignans and isoflavonoids seem to stimulate
sex hormone-binding globulin (SHBG)
synthesis in the liver; in this way, they most
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likely reduce the biological effects of sex
hormones (67,68). An increase in SHBG
results in lowering the percentages of free
testosterone and free estradiol and in reduc-
ing both the albumin-bound and the free
fraction ofthe sex hormones. This reduces
the metabolic clearance rate of the steroids
and, in this way, reduces their biological
activity. In Finnish women total fiber
intake, total fiber intake per kilogram body
weight, and grain fiber intake per kilogram
body weight correlate positively with
urinary excretion of total lignans and
isoflavonoids (67,68). The urinary excre-
tion of the two groups of compounds and
also enterolactone alone in both pre-
menopausal and postmenopausal Finnish
women correlate positively with plasma
SHBG and negatively with plasma percent-
age free estradiol and percentage free testos-
terone [H Adlercreutz, unpublished results;
(67,68)]. In vitrostudies using HepG2 liver
cancer cells showed that enterolactone (49),
genistein (69), and daidzein (M Carson et
al., unpublished data) stimulate SHBG syn-
thesis. This seems to explain the higher
SHBG values in vegetarians with normal
weight (68,70,71).
Lignans, Isoflavonoids,
and Cancer
Table 1 shows a number ofstudies related
to possible anticancer effects of isoflavo-
noids and lignans detected in man. Studies
have been mentioned if the pure com-
pounds have been tested or lignans and/or
isoflavonoids have been measured. Studies
with soy products, with no mention or
measurement of isoflavonoids, have not
been included.
Subjects with breast cancer or at high
risk of breast cancer excrete low amounts
of lignans and isoflavonoids (5,68), but
subjects living in areas with low risk ofhor-
mone-dependent cancers have higher levels
(26,31,59,67,68,109). Finnish subjects
with medium risk of breast and prostate
cancer have relatively high lignan excretion
but low isoflavonoid excretion. Japanese
subjects at low risk have high isoflavonoid
excretion. Interestingly, the biologically
active free+sulfate fraction ofthe lignans is
as high in Japanese men as in Finnish men
(H Markkanen et al., unpublished results),
despite low urinary lignan values and low
lignan glucuronide values in plasma.
Because in Boston and in Finland the lig-
nan excretion is mainly associated with the
intake of grain fiber or whole-grain prod-
ucts [H Adlercreutz, unpublished data;
(31,67)], it seems that in the United States
and Finland the risk may, to a relatively
high degree, depend on the intake ofsuch
products. Higher mean values oflignan in
women were observed in North Karelia
compared to women in the Helsinki area,
which also correlates with breast cancer risk
(31). Intake offruits and berries in Finnish
women has a strong correlation with lignan
excretion (67). Berries contain the seeds
of the plant; these may be rich in lignan
precursors.
In addition to possible inhibitory
effects on cancer cell proliferation, on pro-
duction of estrogens from androgens by
inhibition of the aromatase enzyme, and
on biological activity of sex hormones due
to an effect on SHBG synthesis and clear-
ance ofthese steroids from the circulation,
there is evidence suggesting an effect of
both lignans and isoflavonoids on the
secretion of gonadotrophins and on the
length ofthe menstrual cycle (7,110-112).
It is therefore important for us to know
which type offiber and in which form it is
consumed.
It is somewhat surprising that recent
prospective epidemiological studies do not
show any protective effect of fiber (113)
with regard to breast cancer risk. However,
in this case only the amount oftotal dietary
fiber was determined. Total fiber intake in a
subject tells us relatively little about lignan
content of the diet and rather little about
the effect on the enterohepatic circulation
ofestrogens affecting plasma estrogen levels
(7,114). In agreement with the study of
Pryor et al. (115), it has been observed that
there is a correlation between fiber intake
and menarcheal age in girls (116,117).
This may be due to an effect on the entero-
hepatic circulation of estrogens reducing
plasma estrogen levels, to aloss ofenergyby
increased fecal excretion, or to hormonal
effects ofphytoestrogens associated with the
fiber. In addition, the administration of
bran to rats postpones menarche (118).
Early menarche is associated with increased
breast cancer risk (119). Results of studies
in postmenopausal women in Boston (71)
and in premenopausal women in Helsinki
(120) show that the main and, in fact, the
onlysignificant difference between the diets
ofthebreast cancerpatients and the omnivo-
rous and vegetarian control women was a
lower intake ofgrain products in the breast
cancer subjects. Ifwe compare the diets of
the Boston and Finnish women, the main
difference between them is in the grain and
grain-fiber intake, which is much higher in
the Helsinki women and they have a lower
risk of breast cancer than the Boston
women. This disparity results in differences
in lignan excretion. Further, the fat to grain
fiber ratio (g/g) seems to be an important
additional determinant ofthe enterohepatic
circulation ofestrogens (7,114).
In the Finnish women, the significance
of the positive correlation between the
excretion of lignans and isoflavonoids in
urine and plasma SHBG and the negative
correlations with percentage free estradiol
and percentage free testosterone are
stronger than the separate correlations for
each group of compounds (67). In two
studies we found the lowest SHBG values
in breast cancer patients compared to con-
trol omnivorous and vegetarian subjects
(68,71). In the second part of the
Finlandia project dealing with groups of
postmenopausal women studied for 1 year,
we again found the lowest SHBG values in
the breast cancer groups and in omnivo-
rous women and higher values in the vege-
tarians. There was a significant positive
correlation between urinary total diphenol
excretion and plasma SHBG (R= 0.64;
p<0.001) (49). Plasma SHBG levels are
inversely correlated to plasma insulin (121)
and androgens. Androgens tend to be high
in breast cancer (71) and are likely to play
a role in the pathogenesis of breast and
prostate cancer.
Our hypothesis with regard to the pro-
tective role of phytoestrogens in breast
cancer was supported by studies showing
that powdered soy bean chips, both before
and after denaturation of protease
inhibitors, decrease mammary tumor for-
mation in a rat breast cancer model (77).
Furthermore, linseed, containing high
amounts of lignans, inhibits mammary
carcinogenesis in rats (81,82). Genistein,
found in human, chimpanzee, and cow
urine and in human plasma and feces, is
anticarcinogenic, probably due to its
inhibitory effect on protein tyrosine kinase
(61-64,122) and angiogenesis (98) and
perhaps due to its antioxidative properties
(97). Genistein and other flavonoids have
been shown to be antiproliferative with
regard to breast cancer cells (Table
1)(75,88). 'When fed to rats, soy protein
isolates (which in our experience always
contain isoflavonoids) inhibit mammary
tumor progression (90). Furthermore,
epidemiological evidence obtained in
Singapore indicates that soy intake pro-
tects women for breast cancer (85).
Enterolactone alone (0.5-10 pM) stimu-
lates the growth of MCF-7 cells; in the
presence of estradiol, both in concentra-
tions that slightly stimulate growth or in
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Table 1. Some studies related to possible anticancer effects of isoflavonoids and lignans detected in man.a
Type of cancer Compound orfood Species orcell type Effect or result Reference
Breast cancer
Breast cancer
Breast cancer
Breast cancer
(VAL 12)Ha-ras-
transformed cells
Breast cancer
Prostate cancer
Mitogen-induced
proliferation
Breast cancer
Erythroleukemia
Breast cancer
Melanoma
Myeloid leukemia
Breast cancer
Colon cancer
Leukemia
Breast cancer
Myeloid leukemia
Myeloid leukemia
Prostatic dysplasia
Breast cancer
Embryonal carcinoma
Breast cancer
Mitogen-induced
proliferation
Normal cells
Breast cancer
Prostatitis
Leukemia
Breast cancer
Solid pediatric tumors
Liver cancer
Non-P-glycoprotein-
mediated multidrug-
resistant cells
Leukemia and TPA-
stimulated PMN cells
Placental microsomes
Endothelial cells
Myeloid leukemia
Non-P-glycoprotein-
mediated multidrug-
resistant cells
Gastric cancer
Monoblastic leukemia
Liver cancer
Prostate cancer
Colon cancer
Gastric, esophagus,
colon cancer
Preadipocytes
TPA-mediated skin
tumor
Monocytic leukemia
Lymphoma
Genistein
Dietand phytoestrogen excretion
Diet and phytoestrogen excretion
Diet and phytoestrogen excretion
Genistein
Dietand phytoestrogen excretion
Soy products
Daidzein
Daidzein
Genistein
Soy bean chips
Genistein
Genistein
Flaxseed
Flaxseed
Genistein
Soyfood
Genistein
Genistein
Soyfood
Genistein, biochanin A
Genistein
Heated soy bean protein isolate
Plant lignans
Biochanin A
Enterolactone
Soyfood
Genistein
Flaxseed
Genistein
Enterolactone
Genistein
Genistein
Lignans
Genistein
Daidzein
Genistein
Genistein
Genistein
Genistein
Genistein
Soy intake
Genistein, biochanin A
Biochanin A
Genistein
Genistein
Genistein
MCF-7 cells
Women
Women
Finnish, American,
and Japanese women
NIH 3T3 cells
Women
Men ofJapanese ancestry
Human lymphocytes
ZR-75-1 cells
Mouse MEL cells
Rat
5 cell lines
Human K562 cells
Rat
Rat
Human HL-60, K562 cells
Women in Singapore
ML-1, HL-60 cells
MO7E cells
Male mice
MCF-7 +othercells
Mouse F9 cells
Rat
Human lymphocytes
Embryonal hamstercells
MCF-7 cells
Rat
MOLT-4, HL-60 human cells
Rat
Neuroblastoma, sarcoma
HepG2 cells
K562/TPA
HL-60 and TPA-stimulated
PMN cells
Human
Many differentendothelial cells
HL-60 cells
Many different cell types
HGC-27 cells
U937 cells
HepG2 cells
LNCaP, DU-145 cells
Japanese men, women
Manytypes ofcells
Human
Mouse
Mouse cell line
Rat Nb2 lymphoma cells
Competition with estradiol
Low urinary excretion in women at higher risk
Low urinary excretion in women at higher risk
Low urinary excretion in women at higher risk
Correlation with plasma SHBG
Inhibition of proliferation
Lowest urinaryexcretion in breastcancer
Less risk
Inhibition of proliferation
Inhibition
Induction ofdifferentiation
Inhibition oftumorgrowth
Induction of differentiation
Induction ofdifferentiation
Protective
Protective
Induction ofdifferentiation
High intake associated with low risk
Induction ofdifferentiation
Inhibition of proliferation
Inhibition
Inhibition of proliferation
Induction ofdifferentiation
Inhibition oftumor progression
Inhibition of proliferation
Decreased the metabolism ofbenzo[a]pyrene
Inhibition of proliferation in the presence
of estradiol
Preventive effect
Inhibits cell cycle, progression and growth
Inhibits promotional phase
Inhibition ofproliferation
Stimulation ofSHBG synthesis
Reversal ofresistance
Inhibition ofhydrogen peroxide formation
Inhibition of aromatase
Inhibition ofangiogenesis
Induction ofdifferentiation
Modulation ofdecreased drug accumulation
Growth inhibition
Induction of differentiation
Inhibition of proliferation
Inhibition of proliferation
Reduced risk
Inhibition of proliferation
Inhibition ofaromatase
Inhibition
Cytotoxicity
Growth inhibition
'Mainly studies that discuss the role of isoflavonoids in cancer orthat use pure isoflavonoids have been included.
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(42)
(5)
(31)
(67)
(72)
(68)
(73)
(74)
(75)
(76)
(77)
(78)
(79)
(80,81)
(80,82,83)
(84)
(85).
(86)
(87)
(43)
(88)
(89)
(90)
(91)
(92)
(38)
(93)
(94)
(82)
(95)
(49)
(96)
(97)
(54)
(98)
(99)
(100)
(101)
(102)
(69)
(103)
(104)
(105)
(56)
(106)
(107)
(108)
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lower amounts, the growth was the same
or less than the control (38). The mecha-
nism ofthis phenomenon is unknown.
Prostate Cancer
In Japan and some other Asian countries,
despite the same incidence of latent and
small or noninfiltrative prostatic carcinomas
as in the Western countries, the mortality is
low (123-125). In 1985 after having
found very high urinary excretion of
isoflavonoids in Japanese men (126), we
suggested that this could be due to the
effect of phytoestrogens, particularly
isoflavonoids, inhibiting the growth of the
latent cancers (7,59). In epidemiological
studies, fat and meat show a positive asso-
ciation with prostate cancer mortality, and
cereals show a negative association (4).
Decreased prostate cancer risk has been
found in Adventists men (127) that have a
high consumption of beans, lentils, peas,
and some dried fruits (all dietary sources of
flavonoids) and in men ofJapanese ances-
try in Hawaii (73) who consume much
rice and tofu, a soybean product contain-
ing isoflavonoids (128,129). We have mea-
sured isoflavonoids in 10 different tofu
products by GC-MS (130), and the
daidzein and genistein content varied from
220 to 460 and 580 to 1130 nmole/g,
respectively. Mean consumption of soy
products (except soy sauce) was 39.2 ±36.4
g/day in Japanese men; the intake ofvari-
ous soy products in men and women
showed a strong positive association with
urinary excretion of isoflavonoids (26).
Lignan excretion in Japanese subjects
showed only a positive association with the
intake of pulses, beans, and boiled
unprocessed soybeans. Preparation of tofu
products seems, therefore, to eliminate the
lignan precursors from the beans.
Soy has been found to have a protective
effect with regard to prostatitis in rats (93),
but to my knowledge prostatitis has not
been associated with prostate cancer.
Recently it was found that soy is protective
with regard to prostatic dysplasia in a
mouse model (43). It was also reported
that genistein and biochanin A, the precur-
sor ofgenistein, inhibit the growth ofboth
androgen-dependent and androgen-inde-
pendent prostate cancer cells in cell cul-
tures (103). The well-known therapeutic
effect of estrogens in prostate cancer
would suggest that phytoestrogens may
inhibit prostate cancer-cell growth during
the promotional phase of the disease or
they may influence differentiation, as
shown for genistein, with regard to differ-
ent types ofleukemia and other malignant
cells (Table 1). Recently, an epidemiologi-
cal study ofJapanese subjects showed that
environmental factors such as diet can
substantially impact the likelihood of
developing clinically detectable prostate
cancer later in life (131).
Despite high fat intake, the prostate
cancer incidence in Finland, particularly in
northeast Finland (132), has been much
lower than in the United States but higher
than in Japan. The higher production of
lignans in the gut due to relatively high
intake ofwhole-grain products, particularly
rye bread in the low-incidence rural areas
in Finland, may perhaps explain this phe-
nomenon. The lignans are weaker estro-
gens than the isoflavonoids, but a possible
protective effect may well be independent
from the estrogenic effect.
Thus, epidemiologic studies as well as
cell culture and animal experiments pro-
vide evidence suggesting that isoflavonoids
and perhaps other phytoestrogens like lig-
nans are protective and can lower risk of
prostate cancer during the promotional
phase ofthe disease.
Colorectal and Other Cancers
In 1984 I suggested that the lignans may be
protective with regard to both breast and
colon cancer (6). We have observed a
higher urinary lignan excretion in subjects
consuming a diet that lowers the risk of
colon cancer (133) or living in areas with
low colon cancer risk (30,132). Some epi-
demiologic evidence obtained in Japan
(104) points to lower colon cancer inci-
dence in areas with high tofu consumption;
this is now being further investigated. Five
percent linseed (rich in lignans) in the diet
ofrats seems to protect against colon cancer,
(83) and genistein and biochanin A inhibit
the proliferation of gastric, esophagus, and
colon cancer (101,105).
Extracts from human urine containing
genistein and synthetic genistein have been
shown to inhibit the growth of cells from
solid pediatric tumors such as neuroblas-
tomas (with both normal and enhanced
MYCN oncogene expression), rhab-
domyosarcomas, and Ewing's sarcomas
(95). We showed that such extracts and
synthesized genistein inhibited bFGF-stim-
ulated endothelial cell (bovine brain-
derived capillary endothelial cells)
proliferation and in vitro angiogenesis
(98). Genistein reduced the production of
plasminogen activator and plasminogen
activator inhibitor-i (98) in cloned bovine
microvascular endothelial cells from
adrenal cortex.
Lignans and isoflavonoids of dietary
origin seem to play a role in the prevention
ofseveral types ofcancer. By inhibiting the
effect of growth factors and angiogenesis,
genistein may be more generally an
inhibitor of cancer growth. Lignans and
isoflavonoids may also be a preventive with
regard to some other Western diseases,
particularly cardiovascular diseases and
osteoporosis, due to the estrogenic and
antioxidative effects. The current evidence
is not yet sufficient for any dietary recom-
mendations, and further work is needed
to establish the role of lignans and
isoflavonoids in human health and disease.
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